1. Home
  2. CLB vs OMER Comparison

CLB vs OMER Comparison

Compare CLB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$19.47

Market Cap

772.5M

Sector

N/A

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.90

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
OMER
Founded
1936
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
772.5M
894.8M
IPO Year
1995
2009

Fundamental Metrics

Financial Performance
Metric
CLB
OMER
Price
$19.47
$11.90
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$12.50
$32.50
AVG Volume (30 Days)
361.0K
4.5M
Earning Date
02-04-2026
11-13-2025
Dividend Yield
0.21%
N/A
EPS Growth
25.86
N/A
EPS
0.68
N/A
Revenue
$517,501,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.33
N/A
P/E Ratio
$28.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.72
$2.95
52 Week High
$20.82
$17.65

Technical Indicators

Market Signals
Indicator
CLB
OMER
Relative Strength Index (RSI) 74.09 47.41
Support Level $18.82 $11.85
Resistance Level $19.96 $13.26
Average True Range (ATR) 0.64 1.32
MACD 0.18 -0.46
Stochastic Oscillator 88.35 4.22

Price Performance

Historical Comparison
CLB
OMER

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: